2 years ago

eXmoor pharma Secures USD35M Series A Funding to Launch New Cell and Gene Therapy Center

  • eXmoor pharma, a Bristol, UK-based end-to-end cell and gene therapy (CGT) manufacturing partner, has raised USD35M in Series A funding

  • The round saw participation from Kineticos Ventures and existing investor MVM Partners

  • The company intends to use the funds to launch its Cell and Gene Therapy Centre, a 65,000 sq ft GMP manufacturing facility, purpose-built to develop and manufacture autologous and allogeneic cell therapies, as well as viral vectors.

      • ProblemHealthcare

      "Cell and gene therapy (CGT) companies need a reliable and efficient way to manufacture their products, but current manufacturing options are often expensive, time-consuming, and inflexible."

      Solution

      "eXmoor pharma provides a one-stop solution for CGT manufacturing, offering everything from research to patient delivery. They have a new 65,000 sq ft GMP manufacturing facility that is purpose-built to develop and manufacture autologous and allogeneic cell therapies, as well as viral vectors. "

      Covered on